Nancy Whiting - 20 Feb 2026 Form 4 Insider Report for Caribou Biosciences, Inc. (CRBU)

Reporting relationship: Director
Issuer ticker: CRBU
Reported as of: 20 Feb 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 20 Feb 2026, 17:28:13 UTC
Prior SEC filing: 23 Jun 2025
Next SEC filing: 15 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Barbara G. McClung, as attorney-in-fact

Key filing fact

Nancy Whiting filed Form 4 for Caribou Biosciences, Inc. (CRBU) on 20 Feb 2026.

Key facts

This page summarizes Nancy Whiting's Form 4 filing for Caribou Biosciences, Inc. (CRBU).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 20 Feb 2026, 17:28.

Change

Previous filing in this sequence was filed on 23 Jun 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001880609 Primary reporting owner

Whiting Nancy

Relationship: Director
Address: C/O CARIBOU BIOSCIENCES, INC., 2929 7TH STREET, SUITE 105, BERKELEY
Signature: /s/ Barbara G. McClung, as attorney-in-fact
Signature date: 20 Feb 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CRBU transaction Derivative

Option to purchase Common Stock

Award

Transaction value: $0
Shares: +45,000
Change %
Price: $0.000000
Shares after: 45,000
Date: 20 Feb 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 45,000
Exercise price: $1.80
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

One-twelfth of the shares subject to this option will vest on each monthly anniversary of the grant date such that the option will be fully vested on February 20, 2027, subject to the reporting person continuing to provide service to the Issuer through each such vesting date.